WO2014111588A3 - Use of a reinforced anti-sun protection composition in protection against long uva rays for protecting oneself against herpes attacks induced by exposure to the sun - Google Patents

Use of a reinforced anti-sun protection composition in protection against long uva rays for protecting oneself against herpes attacks induced by exposure to the sun Download PDF

Info

Publication number
WO2014111588A3
WO2014111588A3 PCT/EP2014/051069 EP2014051069W WO2014111588A3 WO 2014111588 A3 WO2014111588 A3 WO 2014111588A3 EP 2014051069 W EP2014051069 W EP 2014051069W WO 2014111588 A3 WO2014111588 A3 WO 2014111588A3
Authority
WO
WIPO (PCT)
Prior art keywords
sun
protection
exposure
reinforced anti
uva rays
Prior art date
Application number
PCT/EP2014/051069
Other languages
French (fr)
Other versions
WO2014111588A2 (en
Inventor
Claire Marionnet
Françoise Bernerd
Françoise Rousset
Olivier De Lacharriere
Original Assignee
L'oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L'oreal filed Critical L'oreal
Publication of WO2014111588A2 publication Critical patent/WO2014111588A2/en
Publication of WO2014111588A3 publication Critical patent/WO2014111588A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Cosmetics (AREA)

Abstract

The invention relates to a cosmetic or dermatological composition comprising, in a physiologically acceptable support, at least one merocyanine compound for preventing reactivation of the herpes simplex virus (HSV) type 1 and/or an outbreak of herpes attacks and/or the occurrence of skin disorders induced by said reactivation and/or said outbreak. It also relates to a method of screening, in vitro or ex vivo,for active agents capable of limiting and/or of inhibiting the modulation of expression of at least one ofthe genes chosen from IFIT1, IFIT2, TLR3, DDX58 or CXCL10.
PCT/EP2014/051069 2013-01-21 2014-01-21 Use of a reinforced anti-sun protection composition in protection against long uva rays for protecting oneself against herpes attacks induced by exposure to the sun WO2014111588A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1350498A FR3001143B1 (en) 2013-01-21 2013-01-21 USE OF A REINFORCED SOLAR PROTECTIVE COMPOSITION IN LIGHT UVA PROTECTION TO PROTECT FROM HERPES PUSH INDUCED BY SOLAR EXPOSURE.
FR1350498 2013-01-21

Publications (2)

Publication Number Publication Date
WO2014111588A2 WO2014111588A2 (en) 2014-07-24
WO2014111588A3 true WO2014111588A3 (en) 2015-04-23

Family

ID=49054618

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/051069 WO2014111588A2 (en) 2013-01-21 2014-01-21 Use of a reinforced anti-sun protection composition in protection against long uva rays for protecting oneself against herpes attacks induced by exposure to the sun

Country Status (2)

Country Link
FR (1) FR3001143B1 (en)
WO (1) WO2014111588A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017037324A1 (en) * 2015-09-04 2017-03-09 Servicio Andaluz De Salud Biomarkers for amyotrophic lateral sclerosis (als)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19811692A1 (en) * 1998-03-18 1999-09-23 Merck Patent Gmbh Sunscreen formulation containing filters preventing herpes virus activation and herpetic skin disease
FR2957251A1 (en) * 2010-03-15 2011-09-16 Oreal Composition, useful for the cosmetic treatment of e.g. skin, comprises silicon-s-triazine substituted by at least two groups of alkylaminobenzoates, and hydrophilic or water soluble merocyanine UV filter, in a medium of UV filter system
FR2957249A1 (en) * 2010-03-15 2011-09-16 Oreal Composition, useful as care products, make-up product, and sunscreen products, comprises dibenzoylmethane derivative, and dicyano derivative or merocyanine cyanoacetate derivative in at least one UV filter system
WO2011113718A1 (en) * 2010-03-15 2011-09-22 L'oreal Composition containing a dibenzoylmethane screening agent and a hydrophilic or water-soluble merocyanin uv-screening agent; process for photostabilizing the dibenzoylmethane screening agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19811692A1 (en) * 1998-03-18 1999-09-23 Merck Patent Gmbh Sunscreen formulation containing filters preventing herpes virus activation and herpetic skin disease
FR2957251A1 (en) * 2010-03-15 2011-09-16 Oreal Composition, useful for the cosmetic treatment of e.g. skin, comprises silicon-s-triazine substituted by at least two groups of alkylaminobenzoates, and hydrophilic or water soluble merocyanine UV filter, in a medium of UV filter system
FR2957249A1 (en) * 2010-03-15 2011-09-16 Oreal Composition, useful as care products, make-up product, and sunscreen products, comprises dibenzoylmethane derivative, and dicyano derivative or merocyanine cyanoacetate derivative in at least one UV filter system
WO2011113718A1 (en) * 2010-03-15 2011-09-22 L'oreal Composition containing a dibenzoylmethane screening agent and a hydrophilic or water-soluble merocyanin uv-screening agent; process for photostabilizing the dibenzoylmethane screening agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROONEY J F ET AL: "PREVENTION OF ULTRAVIOLET-LIGHT-INDUCED HERPES LABIALIS BY SUNSCREEN", THE LANCET, LANCET LIMITED. LONDON, GB, vol. 338, 1 December 1991 (1991-12-01), pages 1419 - 1422, XP002929346, ISSN: 0140-6736, DOI: 10.1016/0140-6736(91)92723-F *

Also Published As

Publication number Publication date
FR3001143A1 (en) 2014-07-25
WO2014111588A2 (en) 2014-07-24
FR3001143B1 (en) 2015-07-31

Similar Documents

Publication Publication Date Title
PH12015500730A1 (en) Inhibitors of histone demethylases
CR20140365A (en) CARBAMATE COMPOUNDS AND PREPARATION AND USE OF THE SAME
ECSP13013035A (en) COMBINATIONS OF ACTIVE COMPOUNDS THAT INCLUDE A DERIVATIVE OF (UNCLE) CARBOXAMIDE AND A FUNGIED COMPOUND
AR090465A1 (en) SOLID FORMS OF A THIOPHOSPHORAMIDATE NUCLEOTIDE PROFARMACO
CL2013001339A1 (en) Condensed heterocyclic derivative compounds, with antiviral activity; pharmaceutical composition that includes them; and its use for the prevention or treatment of HIV infection.
CL2013000727A1 (en) Compounds derived from imidazo [1,2-f] [1,2,4] triazinyl nucleosides; pharmaceutical composition that includes them; and its use for the treatment of a flaviviridae virus infection, particularly hepatitis c virus infections.
CL2011002494A1 (en) Compounds derived from 7-aza-di-spiro- [3.0.4.1] -decan-8-carboxamide; pharmaceutical composition comprising them; and use for the treatment of a disorder associated with the hepatitis c virus (hcv) and the human immunodeficiency virus (hiv).
CL2014001838A1 (en) Compounds derived from fluormethyl-5,6-dihydro-4h- [1,3] oxazin-2-ylamine, as bace1 inhibitors; its process of obtaining; pharmaceutical composition that contains them; and its use for the therapeutic and / or prophylactic treatment of Alzheimer's disease, amyotrophic lateral sclerosis, cancer, cardiovascular diseases and gastrointestinal diseases, among others.
DK2233127T3 (en) Use of antioxidants in the manufacture of a pharmaceutical or cosmetic composition to protect the skin from damage caused by infrared radiation
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
MD20140094A2 (en) Spiro [2.4]heptanes for treatment of Flaviviridae infections
DK1591105T3 (en) Use of antioxidants in the manufacture of a pharmaceutical or cosmetic composition to protect the skin from damage caused by infrared radiation
BR112014012463A2 (en) keratoconjunctive protective agent or keratoconjunctival disorder suppressing agent
WO2014043230A3 (en) Formulations comprising idebenone, n-acetyl-s-farnesyl-l-cysteine and ergothioneine and uses thereof
BR112015014454A2 (en) sunscreen composition and uses and methods for protecting and absorbing keratinous substrate from ultraviolet radiation
IN2014MN01548A (en)
IN2014MN02056A (en)
BR112016022519A8 (en) chromene and 1,1a, 2,7b-tetrahydrocyclopropa [c] chromene pyridopyrazinedione as gamma secretase modulators
WO2016164744A8 (en) Protective action of lutein against blue light on human skin cell lines
ECSP17059323A (en) THESOPHENSIN AND BETABLOCKER COMBINATION FORMULATION
BR112018004731A2 (en) skin care composition, methods for protecting the skin and increasing absorption of spf or uv.
BR112015000789A2 (en) sun protection cosmetic spray
CO6361950A2 (en) COMPOSITIONS, VACCINES AND METHODS OF THE VIRUS OF HERPES OF BOVINE LIVES -1
WO2014116772A3 (en) Squaric derivatives for the treatment of hepatitis c
BR112014015582A2 (en) antiviral compounds

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14701038

Country of ref document: EP

Kind code of ref document: A2